{
    "nct_id": "NCT06390839",
    "official_title": "MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients With Tumors With CDK4 or CDK6 Amplification",
    "inclusion_criteria": "* Patients must have met applicable eligibility criteria in the Master MATCH Protocol EAY131/ NCI-2015-00054 prior to registration to treatment subprotocol\n* Patients must have CDK4 amplification or CDK6 amplification, or another aberration, as determined via the MATCH Master Protocol\n* Patients must have an electrocardiogram (ECG) within 8 weeks prior to treatment assignment and must have no clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g. complete left bundle branch block, third degree heart block)\n* Patients must not have breast cancer, mantle cell lymphoma, myeloma, or liposarcoma\n* Patients must not have known hypersensitivity to palbociclib or compounds of similar chemical or biologic composition\n* Patients with known or symptoms of left ventricular dysfunction will be excluded\n* Patients must not have received prior therapy with a CDK4 or CDK6 inhibitor (including but not limited to palbociclib, abemaciclib, or ribociclib)\n* Patients must not be using drugs or foods that are known potent CYP3A4 inhibitors or inducers, or are CYP3A substrates with narrow therapeutic indices\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}